Literature DB >> 32062725

The emergence of carbapenemase blaNDM genotype among carbapenem-resistant Enterobacteriaceae isolates from Egyptian cancer patients.

Mahmoud M Tawfick1,2, Walaa A Alshareef3, Hager A Bendary4, Hadir Elmahalawy5, Abeer K Abdulall6.   

Abstract

Carbapenem resistance among Enterobacteriaceae is a major concern that is increasingly reported worldwide. The objective of this study is to determine the incidence of carbapenem resistance as well as to investigate for carbapenemase-encoding genes among Enterobacteriaceae clinical isolates from cancer patients at different cancer institutes in Egypt. This determination was a cross-sectional study with a total of 135 clinical isolates collected over a period of 1 year. All isolates were sub-cultured on ChromID agar and subjected to phenotypic and molecular detection of carbapenemases. Most of the Enterobacteriaceae isolates were MDR with high resistance rates against tested antimicrobials. Overall, the results of PCR assays revealed that 89.62% (121/135) of isolates harbored one or more of the carbapenemase-encoding genes, while phenotypic assays revealed the production of carbapenemases in 68.88% (93/135) of isolates. BlastN analysis against the non-redundant genome sequences available in the GenBank database revealed that the blaNDM-1 gene was the most prevalent genotype of carbapenemases in 93/135 (68.88%), followed by blaOXA-48 44/135 (32.59%), blaOXA-23 42/135 (31.11%), and blaKPC-2 2/135 (1.48%). Klebsiella pneumoniae isolates harbored the highest number of carbapenemase-encoding genes 34/121 (28.09%). The high prevalence of carbapenemases and/or their encoding genes among MDR Enterobacteriaceae bacteria in Egypt is alarming, thus, the management of serious infections caused by Enterobacteriaceae, particularly in cancer patients will be challenging to clinicians. Carbapenemase blaNDM genotype is emerging in cancer healthcare settings in Egypt, which could be the cause of the current increase in carbapenemase-producing Enterobacteriaceae.

Entities:  

Keywords:  Cancer patients; Carbapenemases; Enterobacteriaceae; MDR; Resistance; blaNDM

Mesh:

Substances:

Year:  2020        PMID: 32062725     DOI: 10.1007/s10096-020-03839-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  6 in total

1.  Molecular Characterization of Carbapenemase-Producing Klebsiella pneumoniae Isolated from Egyptian Pediatric Cancer Patients Including a Strain with a Rare Gene-Combination of β-Lactamases.

Authors:  Dina Osama; Hadir El-Mahallawy; Mohamed Tarek Mansour; Abdelgawad Hashem; Ahmed S Attia
Journal:  Infect Drug Resist       Date:  2021-01-29       Impact factor: 4.003

Review 2.  Global Threat of Carbapenem-Resistant Gram-Negative Bacteria.

Authors:  Shio-Shin Jean; Dorji Harnod; Po-Ren Hsueh
Journal:  Front Cell Infect Microbiol       Date:  2022-03-15       Impact factor: 5.293

3.  Carbapenem-Resistant Klebsiella pneumoniae Among Patients with Ventilator-Associated Pneumonia: Evaluation of Antibiotic Combinations and Susceptibility to New Antibiotics.

Authors:  Raghdaa A Ramadan; Aya M Bedawy; Essamedin M Negm; Tarek H Hassan; Dalia A Ibrahim; Somia M ElSheikh; Rania M Amer
Journal:  Infect Drug Resist       Date:  2022-07-06       Impact factor: 4.177

4.  Landscape of Multidrug-Resistant Gram-Negative Infections in Egypt: Survey and Literature Review.

Authors:  Amani El-Kholy; Hadir A El-Mahallawy; Noha Elsharnouby; Mohamed Abdel Aziz; Ahmed Mohamed Helmy; Ramy Kotb
Journal:  Infect Drug Resist       Date:  2021-05-24       Impact factor: 4.003

5.  Multidrug-Resistant and Carbapenemase-Producing Enterobacteriaceae in Addis Ababa, Ethiopia.

Authors:  Saba Gebremichael Tekele; Dejenie Shiferaw Teklu; Melese Hailu Legese; Daniel Gebretsadik Weldehana; Melaku Ashagrie Belete; Kassu Desta Tullu; Samuel Kinde Birru
Journal:  Biomed Res Int       Date:  2021-06-11       Impact factor: 3.411

6.  Phenotype-genotype correlations among carbapenem-resistant Enterobacterales recovered from four Egyptian hospitals with the report of SPM carbapenemase.

Authors:  Neveen A Abdelaziz
Journal:  Antimicrob Resist Infect Control       Date:  2022-01-21       Impact factor: 4.887

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.